GenoMethods - Biotechnology, Bioinformatics & AI in Biology

New myasthenia gravis trial results set to reshape neuromuscular medicine at AANEM 2026

Breakthrough phase 3 data and new strategies for myasthenia gravis will take the spotlight at the 2026 AANEM Annual Meeting, pushing clinicians to rethink how they treat patients.

By Elena MacLeod · September 24, 2026, 9:54 AM · 4 mins read

Clinical Trials & Evidence

Gilead ramps up cancer drug trials in Korea, shifting focus beyond antivirals

By Elena MacLeod

Biotechnology News & Analysis

Travere CEO Eric Dube steps down after Filspari breakthrough

By Vivian Lin

Diagnostics & Precision Medicine

M42 opens first Diaverum renal clinic in Kyrgyzstan, marking Central Asia expansion

By Adrian Cole

Clinical Trials & Evidence

Gilead Korea pushes into CAR-T therapies and new drugs in major expansion

By Elena MacLeod

IN-DEPTH REPORTING

Drug Discovery

VERAXA Biotech pushes ahead with BiTAC cancer platform after NASDAQ listing

VERAXA Biotech has joined the NASDAQ and is moving fast on its oncology pipeline built around the BiTAC platform. The Swiss company is entering a new phase.

By Vivian Lin · September 24, 2026, 8:46 AM

Biotech Investing

Europe leaves China biotech IP licensing unchecked as US moves to tighten controls

September 23, 2026, 10:47 AM

Clinical Trials & Evidence

Experimental CAR T cell therapy brings new hope for tough-to-treat colorectal cancer

September 23, 2026, 9:17 AM

BIOTECHNOLOGY NEWS & ANALYSIS >

Biotechnology News & Analysis

Anixa Biosciences locks in exclusive Australian patent for breast cancer vaccine

Anixa Biosciences has secured exclusive Australian rights to its breast cancer vaccine platform through 2040, following strong Phase 1 trial results and a growing global patent portfolio.

By Elena MacLeod · September 22, 2026, 6:01 PM

Clinical Trials & Evidence

Biotechnology News & Analysis

CAR-T therapy transforms relapsed lymphoma into a race for treatment access

September 21, 2026, 7:52 AM

Biotechnology News & Analysis

AI designs new viruses to fight bacteria and rewrites the rules of biotechnology

September 20, 2026, 7:38 PM

Biotechnology, Decoded

GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.

TOP STORIES

New myasthenia gravis trial results set to reshape neuromuscular medicine at AANEM 2026

Gilead ramps up cancer drug trials in Korea, shifting focus beyond antivirals

Travere CEO Eric Dube steps down after Filspari breakthrough

M42 opens first Diaverum renal clinic in Kyrgyzstan, marking Central Asia expansion

Gilead Korea pushes into CAR-T therapies and new drugs in major expansion

IN-DEPTH REPORTING

VERAXA Biotech pushes ahead with BiTAC cancer platform after NASDAQ listing

Europe leaves China biotech IP licensing unchecked as US moves to tighten controls

Experimental CAR T cell therapy brings new hope for tough-to-treat colorectal cancer

FEATURED STORIES

B cell non Hodgkin lymphoma pipeline grows as new trials target aggressive disease

Gene editing and biotech interventions target survival of British wildlife

Liso-cel shows strong real world results in mantle cell lymphoma

GC Biopharma pushes ahead with homegrown mRNA COVID-19 vaccine using full-cycle AI

Sai Life Sciences gets CRISPR Cas9 license for global drug discovery work

New clinical trial data and risk warnings shake up blood cancer care at SOHO 2026

BIOTECHNOLOGY NEWS & ANALYSIS >

Anixa Biosciences locks in exclusive Australian patent for breast cancer vaccine

Australian government funds international CAR-T clinical trials for children

AI-designed genome editors offer new options for rice gene editing

CLINICAL TRIALS & EVIDENCE >

AbbVie pursues dual antibody strategy to reshape lung cancer treatment

CAR-T therapy transforms relapsed lymphoma into a race for treatment access

AI designs new viruses to fight bacteria and rewrites the rules of biotechnology

Biotechnology, Decoded